These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23967714)

  • 21. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain.
    Ruggiero A; Coccia P; Arena R; Maurizi P; Battista A; Ridola V; Attinà G; Riccardi R
    Pediatr Blood Cancer; 2013 Mar; 60(3):433-7. PubMed ID: 23034996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.
    Mercadante S; Ferrera P; Villari P
    Support Care Cancer; 2007 Apr; 15(4):441-4. PubMed ID: 17106658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
    Uberall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
    Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
    Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal opioids for cancer pain.
    Skaer TL
    Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal buprenorphine combined with spinal morphine and naropine for pain relief in chronic peripheral vasculopathy.
    Aurilio B; Pace MC; Passavanti MB
    Minerva Anestesiol; 2005; 71(7-8):445-9. PubMed ID: 16012418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies.
    Louis F
    Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
    Sittl R; Nuijten M; Poulsen Nautrup B
    Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal buprenorphine in the treatment of chronic pain.
    Sittl R
    Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
    Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine and the transdermal system: the ideal match in pain management.
    Budd K
    Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal buprenorphine.
    Evans HC; Easthope SE
    Drugs; 2003; 63(19):1999-2010; discussion 2011-2. PubMed ID: 12962515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buprenorphine TDS: use in daily practice, benefits for patients.
    Radbruch L
    Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Transdermal buprenorphine during pregnancy].
    Ebner E; Wiedmann M
    Schmerz; 2006 Aug; 20(4):334-7. PubMed ID: 16283207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of subcutaneous and transdermal administration of buprenorphine for pre-emptive analgesia in dogs undergoing elective ovariohysterectomy.
    Moll X; Fresno L; García F; Prandi D; Andaluz A
    Vet J; 2011 Jan; 187(1):124-8. PubMed ID: 20056555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.